Rick Scott Warns Beijing's New Drug Rules Could Threaten US Medicine Supply: 'Stop Being Dependent on Communist China'
Rick Scott Warns Beijing's New Drug Rules Could Threaten US Medicine Supply: 'Stop Being Dependent on Communist China'
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Rick Scott Warns Beijing's New Drug Rules Could Threaten US Medicine Supply: 'Stop Being Dependent on Communist China'
Procter & Gamble Q4 Adj. EPS $1.43 Beats $1.41 Estimate, Sales $21.203B Miss $21.379B Estimate
Apple's Incoming CEO John Ternus Signals More Apple TV Growth as Tim Cook Teases More Formula 1-Style Bets: 'We'll Do Things That...'
Procter & Gamble Sees FY2027 GAAP EPS $6.69-$6.95 vs $6.97 Est
Procter & Gamble Sees FY2027 Adj EPS $6.89-$7.11 vs $7.04 Est; Sees Sales $85.127B-$86.813B vs $89.412B Est
Jefferies Maintains Buy on Coca-Cola, Raises Price Target to $104
Bain Capital, Tillman Announce $1.5B Investment In Eaton Fiber To Bring Verizon Fiber Broadband To Over A Million Locations; Verizon To Acquire Ripple Fiber Customers
Visa Delivers Reassuring Read on the US Consumer: No Signs of Spending Weakness
JP Morgan Maintains Overweight on Visa, Raises Price Target to $450
Procter & Gamble Appoints President, CEO Shailesh Jejurikar To Additional Role Of Board Chairman, Effective Aug. 1, Succeeding Jon Moeller
Intel Stock Is Gaining Wednesday: What's Going On?
Baird Maintains Outperform on Visa, Raises Price Target to $420
Microsoft Facing U.K. Competition And Markets Authority Investigation Over Alleged Infringements Of Consumer Protection Law By Microsoft Ireland Operations
Procter & Gamble shares are trading lower after the company reported worse-than-expected Q4 sales results and issued FY27 GAAP EPS guidance below estimates. Also, the company issue…
Microsoft Likely To Report Higher Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Barclays Maintains Equal-Weight on Amgen, Raises Price Target to $360
Analyst Says AI Is Making SK Hynix Less Cyclical—and More Valuable
Barclays Maintains Overweight on Merck & Co, Raises Price Target to $150
Caterpillar shares are trading lower after Baird downgraded its rating on the stock from Outperform to Neutral and lowered its price target from $1200 to $900.
Cantor Fitzgerald Reiterates Overweight on Visa, Maintains $410 Price Target